AGN-190383 | 120755-15-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: AGN-190383
• 英文别名: 1-(2-hydroxy-5-oxo-2,5-dihydrofuran-3-yl)tridecyl acetate；4-(1-acetoxytridecyl)-5-hydroxy-2(5H)-furanone；1-(2-hydroxy-5-oxo-2H-furan-3-yl)tridecyl acetate
• CAS: 120755-15-9
• 化学式: C₁₉H₃₂O₅
• 分子量: 340.46
• InChiKey: QDXHMXIOLIYZHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  AGN-190383 在 铑 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 4-(1-acetoxytridecyl)-5-hydroxy-2-tetrahydrofuranone
  参考文献：
  名称：

  Anti-inflammatory furanones

  摘要：

  新的5-羟基-2-呋喃酮化合物具有抗炎、免疫抑制和抗增殖活性，并可用于治疗银屑病和调节钙平衡。

  公开号：

  US05134128A1
• 作为产物：
  描述：

  2-Triethylsilyl-4-(1-hydroxy-tridecyl)-furan 在 rose bengal 水 、 氧气 作用下， 以 四氢呋喃 为溶剂， 反应 0.75h， 以86%的产率得到AGN-190383
  参考文献：
  名称：

  Singlet oxygen oxidation of substituted furans to 5-hydroxy-2(5H)-furanone

  摘要：

  The conditions for the regiospecific singlet oxygen oxidation of various 2,4-disubstituted furans 9 to 4-substituted-2 (5H)-furanones 3 are developed. The presence of a C-2 substituent (e.g., trimethylsilyl, tert-butyldimethylsilyl, or tributylstannyl) in 9 is an absolute requirement for the formation of the 4-substituted-5-hydroxy-2(5H)-furanone regioisomer 3. When the C-2 substituent is triethylsilyl (TES) or TBDMS, however, apart from 3, the corresponding 5-trialkylsiloxy derivative 11 is also isolated in a significant amount. These silyl acetals are unexpectedly stable but can be hydrolyzed back to 3 on stirring with dilute acid. The formation of silyl acetals, to our knowledge, has never been reported in the singlet oxygen oxidation of (trialkylsilyl)furan. A plausible mechanism for their formation is proposed. The presence of a catalytic amount of water in the oxidation of 2-(trialkylsilyl)-4-substituted-furans not only eliminates the formation of the silyl acetals but also speeds up the rate of the oxidation process. Moreover, the oxidation can then be carried out at 0-degrees-C instead of at -78-degrees-C. Oxidation of 2-(1-hydroxyalkyl)-4-substituted-furans in the absence of a reducing agent gives little or no sign of 2,5-disubstituted-6-hydroxy-3(2H)-pyranone 23 but instead 26 selectively. Thus, the (1-hydroxy)alkyl group can be utilized as the trialkylsilyl or trialkylstannyl group in dictating the regioselectivity in the singlet oxygen oxidation of substituted furans.

  DOI：

  10.1021/jo00025a012

文献信息

• Intermediates and processes for preparing 4-substituted 2-5(H)-furanones
  申请人：Allergan, Inc.

  公开号：US05082954A1

  公开（公告）日：1992-01-21

  Anti-inflammatory 4-substituted 2-furanones are made from intermediates having the formulas: ##STR1## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons; X is H, OH, NH.sub.2, I or Br; R.sub.4 is H, alkyl of 1-20 carbons, phenyl[C.sub.1 -C.sub.20 alkyl], naphthyl[C.sub.1 -C.sub.20 alkyl], CH.sub.2 OH, CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 OH, CH.sub.2 --CHO, CH.sub.2 --COOH or CH.sub.2 --COOR.sub.5, and R.sub.5 is alkyl of 1 to 6 carbons, with the proviso that when X is hydrogen then R.sub.4 is selected from the group consisting of CH.sub.2 OH, CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 OH, CH.sub.2 --CHO, or CH.sub.2 --COOR.sub.5 ; ##STR2## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl or 1 to 6 carbons, and R.sub.5 is alkyl or 1 to 6 carbons; ##STR3## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons, and R.sub.6 is phenyl, or alkyl of 1 to 6 carbons, and ##STR4## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons.

  抗炎症的4-取代的2-呋喃酮是由具有以下结构的中间体制备的：##STR1## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基；X是H，OH，NH.sub.2，I或Br；R.sub.4是H，1-20个碳原子的烷基，苯基[C.sub.1-C.sub.20烷基]，萘基[C.sub.1-C.sub.20烷基]，CH.sub.2 OH，CH.sub.2 NH.sub.2，CH.sub.2 CH.sub.2 OH，CH.sub.2 --CHO，CH.sub.2 --COOH或CH.sub.2 --COOR.sub.5，而R.sub.5是1到6个碳原子的烷基，但当X为氢时，R.sub.4从CH.sub.2 OH，CH.sub.2 NH.sub.2，CH.sub.2 CH.sub.2 OH，CH.sub.2 --CHO或CH.sub.2 --COOR.sub.5的组中选择；##STR2## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基，而R.sub.5是1到6个碳原子的烷基；##STR3## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基，而R.sub.6是苯基，或者1到6个碳原子的烷基，以及##STR4## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基。
• [EN] PHARMACEUTICAL COMPOSITIONS CONTAINING 3 AND 4-SUBSTITUTED 2(5H)-FURANONES FOR INHIBITING BONE LOSS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES CONTENANT DES 2(5H)-FURANONES A SUBSTITUTION EN POSITIONS 3 et 4 DESTINEES A INHIBER LES PERTES OSSEUSES
  申请人：ALLERGAN, INC.

  公开号：WO1993021915A1

  公开（公告）日：1993-11-11

  (EN) 3 and 4-substituted 2(5H)-furanone compounds influence the balance between bone production and bone resorption in mammals, including humans. The active compounds are administered to mammals, including humans, in an effective dose which ranges between 0.05 to 100 mg per kilogram, body weight, per day, for the purpose of influencing the balance between bone production and bone resorption, and particularly for treating osteoporosis.(FR) L'invention se rapporte à des composés de 2(5H)-furanone à substitution en positions 3 et 4 qui agissent sur l'équilibre de la formation osseuse et de la résorption osseuse chez les mammifères ainsi que chez l'homme. Les composés actifs sont administrés aux mammifères ainsi qu'à l'homme, en une dose efficace comprise entre 0,05 et 100 mg par kilo/poids/jour afin d'agir sur l'équilibre entre la formation osseuse et la résorption osseuse, et notamment pour traiter l'ostéoporose.

  EN：3 和 4-取代的 2(5H)-furanone 化合物影响哺乳动物（包括人类）骨生成和骨吸取的平衡。活性化合物被给予包括人类在内的哺乳动物，以有效剂量（0.05 到 100 毫克每公斤体重，每日一次），用于影响骨生成和骨吸取的平衡，特别用于治疗骨质疏松。 FR： invention pertient à des com posés de 2(5H)-furanone à substitution en position 3 et 4 qui agissent sur l'équilibre de la formation ossaire et de la dissolution ossaire chez les mammifères et l'iTl homme. Les com posés actifs sont soumis aux mammifères et l'iTl Wesley, en dose effective comprise entre O,05 et 100 mg par kilogramme par jour, avant d'avoir pour objectif d'agir sur l'équilibre entre la formation ossaire et la dissolution ossaire, et en particulier pour traiter l'ostéoporose.
• PHARMACEUTICAL COMPOSITIONS CONTAINING 3 AND 4-SUBSTITUTED 2(5H)-FURANONES FOR INHIBITING BONE LOSS
  申请人：ALLERGAN, INC.

  公开号：EP0637240A1

  公开（公告）日：1995-02-08
• US5082954A
  申请人：——

  公开号：US5082954A

  公开（公告）日：1992-01-21
• US5134128A
  申请人：——

  公开号：US5134128A

  公开（公告）日：1992-07-28